Business Wire

Board Unveils New Foresight and Signals Products: Revolutionizing Business Planning with AI and Economic Intelligence

19.2.2025 15:00:00 CET | Business Wire | Press release

Share

Board, the leading Enterprise Planning Platform, is transforming the way businesses anticipate and adapt to economic shifts with today’s announcement of Board Foresight and Board Signals. These cutting-edge solutions, developed as a result of Board’s recent acquisition of Prevedere, empower enterprises with real-time economic indicators, predictive analytics, and the expertise of Board’s in-house economists—all backed by exclusive access to over 5 million global datasets.

This release marks a huge step forward in completing Board’s product vision. By harnessing the power of macroeconomic intelligence, the Board Enterprise Planning Platform now enables more comprehensive, collaborative, and continuous planning capabilities than ever before. Board Foresight and Signals give business leaders the ability to look beyond internal historical data, forecast with greater accuracy, scenario plan with more agility, and make strategic decisions with confidence in an increasingly volatile world.

Board Foresight: Continuous planning with external data, AI, and predictive analytics

Board Foresight takes business forecasting to the next level by unlocking the power of external data with expert-curated economic indicators, an advanced correlation engine, and predictive analytics. With real-time updates from millions of external sources, Board Foresight enables enterprises to anticipate market shifts, align business strategies and drive continuous planning.

Key benefits of Board Foresight:

  • Expert-Curated Indicators: Get a list of the external factors most likely to impact your industry.
  • Powerful Correlation Engine: Connect to your own internal time series data and Foresight will run millions of models to identify your most relevant performance drivers.
  • Results Explained by AI: Get a complete understanding of the external factors impacting your business, with clear explanation and interpretation delivered through generative AI.
  • Predictive Forecasting to Support Continuous Planning: Forecast with better accuracy and turn continuous planning into a competitive advantage.

Learn more at https://www.board.com/en/product/foresight.

Board Signals: Make smarter strategic decisions with expert-curated external data

Board Signals provides decision-makers with real-time, industry-specific economic indicators to help them navigate market volatility with confidence. Designed for strategic planners, executive officers, and board members, Board Signals delivers clear, actionable intelligence to drive smarter business decisions and is available today.

Key benefits of Board Signals:

  • Industry-Specific Economic Intelligence: Get expert-curated indicators tailored to your industry, monitored and updated regularly by Board’s in-house economists.
  • Smart Alerts on Market Volatility: Receive real-time alerts on headwinds and tailwinds impacting your business so you can respond in an agile manner to capitalize on opportunities and mitigate risks.
  • Indicator Reports and Industry Outlook Score: Visualize economic conditions with intuitive reports and scoring to support strategic decision-making.

Learn more at https://www.board.com/en/product/signals.

An Innovative Breakthrough in Enterprise Planning

David Marmer, SVP of Product at Board, emphasized the significance of these new solutions:

“The introduction of Board Foresight and Board Signals marks a new beginning for enterprise planning. For too long, businesses have relied solely on historical internal data, missing the critical external factors that drive success or failure. With the power of over 5 million datasets, AI-driven analytics, and expert economic intelligence, our customers can now plan continuously for the future with greater confidence and precision. These innovations reflect Board’s commitment to giving our customers the tools they need to stay ahead.”

Visionary Brands are Leading the Way

Leading enterprises are already leveraging Board Signals and Board Foresight to enhance their decision-making. Milwaukee Tool, Whataburger, and Kraft Heinz are among the early adopters benefiting from these solutions, using them to navigate economic volatility, optimize inventory, and drive strategic growth.

“This has been a game-changer for Whataburger,” says Pete Valadez, Senior Director of Financial Planning & Analysis at Whataburger. “By incorporating external data and predictive analytics into our forecasting process, we’ve been able to dramatically improve our accuracy and avoid missed expectations. The real-time alerts and collaborative nature of the solution have empowered our entire team to make data-driven decisions with confidence.”

General Availability

Board Signals and Board Foresight are available now globally.

About Board

The Board Enterprise Planning Platform powers financial and operational planning for more than 2,000 organizations worldwide. Industry leaders trust Board to turn complex data into better decisions with AI, analytics, and tailor-made solutions for enterprise-grade challenges. Global brands including H&M, BASF, Burberry, Toyota, Coca-Cola, KPMG, and HSBC use Board to enhance workflows and strengthen their competitive edge. Founded in 1994, and now with 25 offices worldwide, Board is recognized by leading analysts including Gartner, IDC, and BARC.

For more information, visit www.board.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219004034/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye